Digoxin for atrial fibrillation: a drug whose time has gone?
about
Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillationManagement of the older person with atrial fibrillation.Atrial Fibrillation: The New Epidemic of the Ageing WorldAtrial fibrillation: prevalence and management in an acute general medical unit.A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation ProjectAssessment of new onset postcoronary artery bypass surgery atrial fibrillation: current practice pattern review and the development of treatment guidelines.Ventricular rate control in the elderly: is digoxin enough?Emergency management of atrial fibrillationDistribution of fast heart rate episodes during paroxysmal atrial fibrillationThe safety of digoxin as a pharmacological treatment of atrial fibrillation.Atrial fibrillation: insights from clinical trials and novel treatment options.Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease.Transient ST Elevation in Vagally Mediated Atrial Fibrillation.Digoxin: its role in contemporary medicine.Dysrhythmias in acute myocardial infarction: how to treat, when to treat, and when not to treat.Atrial fibrillation and dilated cardiomyopathy: therapeutic strategies when sinus rhythm cannot be maintained.Atrial fibrillation: a review of mechanism, etiology, and therapy.Pharmacologic management of atrial fibrillation.Risk of complications of atrial fibrillation.Cardioversion of atrial fibrillation.Managing atrial fibrillation in active patients and athletes.Ventricular response during lungeing exercise in horses with lone atrial fibrillation.Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil.Drugs for atrial fibrillation.Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future Challenges
P2860
Q24804548-5CE19134-9F40-4EBF-9AAE-0C182D6C56EDQ33144789-DFF0C7FC-707D-439B-BD7E-DBCE76CA7476Q33168630-B47D61A1-5E66-4050-90B1-0B28448C056DQ33592414-0E9FD81A-64F2-41AC-B4ED-813E16D3D256Q34214562-5313F9F7-9081-4D66-9535-BAA64B1F2411Q34532607-DADFD610-5AE0-4031-A8CF-03FB3A5374F4Q34989723-BCB8E614-1446-42A7-87B8-0598CC073B23Q35168643-D3F488BC-6249-401D-8BCA-079DDEC8F404Q35367653-78745946-B8A0-43DB-91F9-88D1DE51ED0AQ36446911-767FBD12-6226-429B-B7C2-683AB97C933EQ37008941-9BC93549-02E1-4C53-B3DE-22C8BC950BA4Q37115706-3AC9594E-5E64-4493-8C5C-5B39881FE4B5Q37495866-CF97F05F-B5F1-4085-95CB-EC0F04F45AB0Q38565140-EDCA1058-0D5F-459E-AE7E-FDA5F5835BC1Q40493090-4CFE987A-EE60-4569-8315-6498EDD8D7CDQ41395583-2A29BA15-DBCF-4569-98DB-E267BE5C94CCQ41529303-B984A976-7B40-4E10-B129-4799FB438A3EQ41561795-F1AC4CEF-84A2-4595-8888-94DCCFBB8631Q41633739-A6966641-39EA-4E83-854A-9BB805AE501DQ43239372-A3441D02-BC3B-4746-AB4E-36291A2A2859Q46259162-24AE452E-E863-4B47-ADC8-C2F54B225DB0Q49149875-3DA8A754-054B-43A3-B05B-B862F0BBAA27Q50755775-A70CACB8-0C20-47AC-9261-DBDAA38916CDQ55397550-BA4975AF-34B7-4631-BCBC-00D3156C48D4Q57161239-77FBB5E2-646E-4118-BBE9-EE95EC993988
P2860
Digoxin for atrial fibrillation: a drug whose time has gone?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Digoxin for atrial fibrillation: a drug whose time has gone?
@en
Digoxin for atrial fibrillation: a drug whose time has gone?
@nl
type
label
Digoxin for atrial fibrillation: a drug whose time has gone?
@en
Digoxin for atrial fibrillation: a drug whose time has gone?
@nl
prefLabel
Digoxin for atrial fibrillation: a drug whose time has gone?
@en
Digoxin for atrial fibrillation: a drug whose time has gone?
@nl
P1476
Digoxin for atrial fibrillation: a drug whose time has gone?
@en
P2093
P304
P356
10.7326/0003-4819-114-7-573
P407
P577
1991-04-01T00:00:00Z